Unsealed documents
suggest medical-device firm knew about hip implant risks.
In a
front-page story, the New York Times (1/23, A1, Meier, Subscription
Publication, 1.68M) continues coverage of the lawsuits Johnson & Johnson
faces over its 2011 hip implants recall, noting that newly disclosed court
records revealed that an "internal analysis" J&J conducted
shortly after issuing the recall "estimated that the all-metal device
would fail within five years in nearly 40 percent of patients who received
it." A trial, which is slated to begin Friday, will consider what
"officials of Johnson & Johnson's DePuy Orthopaedics division knew
about the device's problem before its recall" and what, if any, actions
they took to remedy the problem. The forthcoming trial is also expected to
"provide a guide to the consequences" of the Articular Surface
Replacement device issue both in terms of J&J's "finances and its
reputation."
Bloomberg News (1/23, Voreacos, Feeley) notes
that J&J's admission on the internal review's estimation that 37 percent of
the devices would "fail within 4.6 years," was revealed in
"documents unsealed Jan. 18 in the lawsuit of Loren Kransky in state court
in Los Angeles. Jurors are scheduled to hear opening statements on Jan. 25 in
Kransky's case, the first to go to trial against J&J."
The Wall Street Journal (1/23, B2, Rockoff,
Subscription Publication, 2.29M) adds that a J&J spokesperson said that the
company is presently facing about 10,000 lawsuits and thus far, it has incurred
about $900 million in charges related to the all-metal ASR devices. Ultimately,
analysts are projecting that J&J's legal liability costs will surpass $1
billion
No comments:
Post a Comment